Defining better intervention strategies for individuals diagnosed with aggressive cancers.

Our Focus

A translational research department providing therapeutic and diagnostic development capabilities focused on the evaluation and application of emerging technologies in cancer care.

By conducting research to obtain a better understanding of disease classification and targeted therapies, Experimental Therapeutics (ET) endeavors to define better intervention strategies for individuals with aggressive cancers. ET is well respected internationally for its track record of proficiency and efficiency when linking preclinical and clinical research, and is focused on the critical need to rapidly establish the therapeutic value of emerging technologies through validated assessments in preclinical models of cancer and in patients.

What We Do

Experimental Therapeutics has a variety of drug development capabilities, including preclinical models (cell-based and animal-model based models) and formal capabilities to support some GLP studies (Rodent GLP) and GMP manufacturing. Our research ranges from development of nanomedicines to identification of unique, targetable, proteins in cells. 

News & Events

Research Labs & Principal Investigators

Recent Publications

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Genome medicine, 2019
Shrestha, Raunak, Nabavi, Noushin, Lin, Yen-Yi, Mo, Fan, Anderson, Shawn, Volik, Stanislav, Adomat, Hans H, Lin, Dong, Xue, Hui, Dong, Xin, Shukin, Robert, Bell, Robert H, McConeghy, Brian, Haegert, Anne, Brahmbhatt, Sonal, Li, Estelle, Oo, Htoo Zarni, Hurtado-Coll, Antonio, Fazli, Ladan, Zhou, Joshua, McConnell, Yarrow, McCart, Andrea, Lowy, Andrew, Morin, Gregg B, Chen, Tianhui, Daugaard, Mads, Sahinalp, S Cenk, Hach, Faraz, Le Bihan, Stephane, Gleave, Martin E, Wang, Yuzhuo, Churg, Andrew, Collins, Colin C

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019
Flores-Morales, Amilcar, Bergmann, Tobias B, Lavallee, Charlotte, Batth, Tanveer S, Lin, Dong, Lerdrup, Mads, Friis, Stine, Bartels, Anette, Kristensen, Gitte, Krzyzanowska, Agnieszka, Xue, Hui, Fazli, Ladan, Hansen, Klaus H, Røder, Martin A, Brasso, Klaus, Moreira, José M, Bjartell, Anders, Wang, Yuzhuo, Olsen, Jesper V, Collins, Colin C, Iglesias-Gato, Diego

ONECUT2 is a driver of neuroendocrine prostate cancer.

Nature communications, 2019
Guo, Haiyang, Ci, Xinpei, Ahmed, Musaddeque, Hua, Junjie Tony, Soares, Fraser, Lin, Dong, Puca, Loredana, Vosoughi, Aram, Xue, Hui, Li, Estelle, Su, Peiran, Chen, Sujun, Nguyen, Tran, Liang, Yi, Zhang, Yuzhe, Xu, Xin, Xu, Jing, Sheahan, Anjali V, Ba-Alawi, Wail, Zhang, Si, Mahamud, Osman, Vellanki, Ravi N, Gleave, Martin, Bristow, Robert G, Haibe-Kains, Benjamin, Poirier, John T, Rudin, Charles M, Tsao, Ming-Sound, Wouters, Bradly G, Fazli, Ladan, Feng, Felix Y, Ellis, Leigh, van der Kwast, Theo, Berlin, Alejandro, Koritzinsky, Marianne, Boutros, Paul C, Zoubeidi, Amina, Beltran, Himisha, Wang, Yuzhuo, He, Housheng Hansen
Back to top